Pulse pressure (PP) is emerging as a major pressure predictor of cardiac disease. The study comprised 10 185 untreated patients with essential hypertension. A total of 5395 men and 4790 women 56713 years old, with uncomplicated essential hypertension, after a 15-day washout period and after 6 months of antihypertensive monotherapy were included. All patients included in the final cohort were responders and had normalized their blood pressure. PP was decreased least with diuretics (À5 mm Hg) and most with angiotensin II receptor blockers (ARBs) and calcium antagonists (À15 mm Hg), followed by angiotensin-converting enzyme inhibitors (ACEI) (À12 mm Hg) a-and b-blockers (À10 and À9 mm Hg), differentiating among antihypertensive classes (Po0.001). The magnitude of PP fall was related to the degree of left ventricular (LV) mass reduction (Po0.001), seen best with ARBs (r ¼ 0.42) and least with ACEIs (r ¼ 0.18). Of the antihypertensive medications used in everyday practice, PP decrease may be achieved best with ARBs and calcium antagonists, whereas diuretics confer poor response. PP was decreased least with diuretics (À5 mm Hg) and most with ARBs and calcium channel blockers (À15 mm Hg), followed by ACEI (À12 mm Hg) a-and b-blockers (À10 and À9 mm Hg), differentiating among antihypertensive classes (Po0.001). Of the antihypertensive medications used in everyday practice, PP decrease may be achieved best with ARBs and calcium antagonists.
Introduction
Arterial hypertension is well established as an independent and major risk factor for coronary heart disease, stroke, aortic aneurysm and renal failure. 1 Evidence from animal and human studies point out that pulse pressure (PP) correlates positively with carotid atherosclerosis 2 and with white matter lesions. 3 A 20-year follow-up study found that PP is associated with higher mortality in both normotensive and hypertensive subjects. 4 Fang et al. 5 proposed that this is true as well for young normotensive persons with low risk of cardiovascular disease.
Analysis of the EURODIAB study showed an association of age with PP in young type I diabetic individuals, stronger in the presence of microvascular complications. 6 The same authors in an other study found that in type II diabetes, PP is positively associated with cardiovascular mortality. 7 PP can be considered as a marker of an ageassociated increase in arterial stiffness, manifested by an increase in systolic (SBP) with parallel decrease in diastolic blood pressure (DBP). 8 Miwa et al. 9 reported that PP is an independent and the most powerful predictor of all pressure components of the progress of aortic calcification.
Antihypertensive drug therapy, based on current guidelines, focuses on office measurements of SBP and DBP reduction, but does not offer any advice for PP measurement and effects. The sixth Joint National Committee (JNC-VI) classification system of blood pressure (BP) emphasizes both SBP and DBP, but also mentions that PP may be a risk for cardiovascular disease as well. In the JNC 7 report, while desired SBP and DBP levels are mentioned, no attention to the PP levels is given. 10 Only few studies have examined the effect of antihypertensive treatment on the magnitude of PP reduction. 11 Similarly, there is a lack of information about the therapy needed to achieve optimal PP values.
The purpose of this study was to evaluate the effect of usual antihypertensive regimens on PP reduction after 6-month therapy, as well as to examine if there is any parallel behaviour of PP and left ventricular (LV) mass regression.
Materials and methods

Study population
We studied retrospectively 11 148 consecutive untreated patients with uncomplicated essential hypertension, 5939 men and 5209 women 56.1712.6 years old, from the Hypertension Units of the Cardiology Departments of Athens University and Onassis Cardiac Surgery Center, enrolled through 1986-2004. Patients already on antihypertensive treatment (42%) were evaluated after an at least 15-day wash-out period.
Hypertension was defined according to the JNC 7 criteria as sitting SBP X140 mm Hg and/or DBP X90 mm Hg as measured by sphygmomanometry. A mercury sphygmomanometer was used, with three readings 1 min apart, and the mean value was calculated. PP was defined as the difference between SBP and DBP. Full clinical and laboratory evaluation was carried out in all patients.
Secondary hypertension, acute or chronic inflammatory diseases, endocrinopathies, renal insufficiency (serum creatinine 41.5 mg/dl), chronic obstructive or other lung diseases, history of a cerebrovascular event, heart failure, coronary artery disease, type I diabetes mellitus, severe obesity with body mass index (BMI) 436 kg/m 2 or inadequate compliance were causes of exclusion from the study. Obesity was defined when BMI was 427 kg/m 2 . High waist/hips ratio was defined when 40.9 in men and 40.8 in women. Type II diabetes mellitus and impaired glucose tolerance (IGT) were defined according to the criteria of the American Diabetes Association.
Patients were divided into six groups according to the antihypertensive therapy with thiazide diuretics, b-blockers, a-blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) ( Table 1 ). To achieve DBP target, drug dosages were uptitrated to the maximally tolerated monotherapy dose, whereas no additional medication was used over the 6 months of the study. Patients with drug-related unwanted effects were dropped from the study. All patients were re-examined bimonthly and re-evaluated after 6 months of antihypertensive monotherapy. The final cohort included patients who normalized their DBP (DBP o90 mm Hg or DBP reduction 410 mm Hg from baseline). BP before and post-therapy was recorded and the percentage difference (%D) in SBP, DBP, PP and LV dimensions were calculated.
Echocardiography study
All patients underwent a complete echocardiographic study on baseline and study end. Patients with no readable echocardiograms were not included in the final cohort. Ultrasound measurements were performed with an ALT Ultramark 8 and 9 apparatus with no knowledge of patient BP levels. LV dimensions and wall thickness were measured from the two-dimensional derived M-mode tracings at the level of the chordae tendineae. The enddiastolic (EDD) and the end-systolic (ESD) diameter, the posterior wall (PW) and the intraventricular septum (IVS) thickness were measured. The measurements were obtained according to the Penn convention criteria. LV mass was calculated according to Devereux et al. 12 and was corrected by body surface area (BSA):
3 )ÀEDD 3 )À13.6/BSA, and by body height raised to the 2.7 power. The reproducibility of LV volume measurement in our laboratory is high, with an interobserver variability less than 5% and intraobserver variability o3%, with r values in the order of 0.98.
Statistics
Continuous variables are presented as mean values7s.d., while qualitative variables are presented as absolute and relative frequencies. Univariate analysis was initially applied to test the associations of difference of LVMI with the difference of PP as well as the associations between various characteristics of the participants and both the outcome and main effect of interest. Comparisons between normally distributed continuous variables and categorical variables were made using the Student's t-test. Correlations between normally distributed continuous variables were evaluated by calculating the Pearson's r-coefficient. The associations between difference of LVMI (dependent variables) and difference of PP were also tested through multiple linear regression analysis. The results obtained from the regression models are presented as b-coefficients and the 95% confidence intervals of the coefficient of the difference of PP. The explanatory variables entered in each multivariate model were: (a) the variables that showed a significant association with 
Results
Our study patients were classified into the abovementioned six groups according to the antihypertensive therapy (Table 1) . The male/female ratio as well as the habit of smoking, incidence of IGT and type II diabetes mellitus were similar in the six treatment groups, although patients on b-blockers were younger and on calcium antagonists were older (Po0.001).
BP and heart rate values before and after treatment are shown in Table 2 . Maximal SBP and DBP fall was observed in patients who received either ARBs or CCBs followed by ACEIs, diuretics, b-blockers and a-blockers (Po0.001). Maximal PP fall was observed in patients who received either ARBs or CCBs (À15 mm Hg) and followed by ACEIs (À12 mm Hg), whereas PP reduction with diuretics (Po0.001) was smaller (À5 mm Hg). ARBs and CCBs did not differ as regards PP fall (P ¼ NS), as did a-and b-blockers. The magnitude of BP fall with the six ARBs used was uniform (P ¼ NS), as shown in Table 3 .
LVMI values and changes before and after treatment are shown in Table 4 . ACEIs and ARBs achieved the greatest LVMI reduction (À13%) followed by CCBs, whereas a-and b-blockers achieved moderate LVMI regression, and diuretics were the least effective in LVMI reduction (À2.7%). Results were similar, using the LVM/H 2.7 index. Again, all these differences were significant (Po0.0001).
The magnitude of LV hypertrophy regression was related (Po0.0001) to PP fall in all drug groups (Table 5 and Figure 1 ). The strongest relation was seen in the ARB group (r ¼ 0.42) and the weakest in the ACEI group (r ¼ 0.18), whereas all the other drug groups had intermediate relationships. These relationships remained significant after correction for confounders in multifactorial analysis. LV hypertrophy regression was related to SBP and PP fall, although it was not related to DBP reduction.
Discussion
Our data show that antihypertensive medications used in every day practice have different effect on PP decrease, achieving the best result with ARBs and CCBs, while PP fall magnitude was related to the degree of LV mass reduction. Data from the Framingham study restricted to persons over 50 Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; BP, blood pressure; CCBs, calcium channel blockers; DBP, diastolic blood pressure; HR, heart rate; PP, pulse pressure; SBP, systolic blood pressure.
Pulse pressure response and antihypertensive treatment EA Karpanou et al years old showed that the association with coronary heart disease risk, although positive both for SBP and DBP, was strongest for PP. 13 Domanski et al., 14 reported that cardiovascular disease risk assessment is improved by considering simultaneously both SBP and DBP, not just SBP, DBP or PP separately. On the other hand, results of a large prospective cohort study indicate a great complexity in the relationship of PP with mortality, depending on age and interactions with both SBP and DBP, and thus discouraging its use for prognostic or therapeutic decisions. 15 Nevertheless, a meta-analysis of three trials in older subjects has shown that PP but not mean BP is the major determinant of cardiovascular risk. 16 Taking into account the fact that all studies till now have demonstrated the importance of PP in the determination of cardiovascular risk, the choice of the best antihypertensive regimen for optimal PP reduction is very significant. Our study agree with that of Takami et al. 11 who demonstrated that ARBs Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HR, heart rate; PP, pulse pressure; SBP, systolic blood pressure. yielded the largest reduction in PP, followed by the ACEI and N-type CCBs. Additionally, PP has been shown to predict LV hypertrophy 17, 18 and target organ damage in essential hypertension, whereas its increase is accompanied by higher risk of heart failure. 19 In patients with a low LV ejection fraction, PP is a strong predictor of myocardial infarction, 20 cardiovascular and all-cause mortality. 21 In the Balloon Angioplasty Revascularization Investigation (BARI) study, an independent association of PP and total mortality after revascularization was found. 22 Furthermore, findings of the multicentre ESCAPP study showed that aortic PP was significantly related to the presence and extent of coronary artery disease in patients without antihypertensive therapy. 23 It is surprising that in various mega trials addressing the performance of various treatment modalities for hypertension, their influence on PP is not taken into account. Currently, the choice of the drug for the initial treatment of hypertension is very strongly debuted. Although ARBs have been shown superior to b-blockers in the LIFE study 24 and ACEI better than diuretics in the Captopril Prevention Project (CAPPP) trial, 25 these findings have not been confirmed. On the contrary, the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT) results suggest that chlorothalidone was better than lisinopril, both in lowering BP and diminishing cardiovascular events, but no differential effects of drug class on PP were found when all participants were considered. 26 In the Hypertension Optimal Treatment (HOT) study, only the degree of DBP reduction was used to assess cardiovascular outcomes. 27 An analysis of the NHANES III did not detect any difference in PP fall for any medication class compared with the referent b-blocker group after adjustment for covariates, but in the subgroup of subjects over 72 years, diuretics decreased PP most. 28 In the REASON study, Pannier et al. 29 found that a very low-dose perindopril/indapamide combination decreases SBP and PP to a larger extent than does a b-blocker after a 12-month treatment. Polonia et al. 30 found that ACEIs or ARBs appear to have a more favourable profile on aortic stiffness, central pressures and aortic wave reflection comparing to b-blockers and CCBs.
The present study agrees with the above beneficial actions of renin-blocking drugs and calcium antagonists, but does not confirm the superiority of diuretics on PP reduction. This may probably be owing to the relative short duration and the retrospective character of the study. In addition, the Pulse pressure response and antihypertensive treatment EA Karpanou et al population of this study was relatively young with mostly combined systolic and diastolic hypertension. This means that arterial stiffness was probably not prominently present. An older population with increased arterial stiffness may have responded better with diuretic therapy.
Our study can be considered interesting, as guidance for drug choice for effective PP reduction leading to LV hypertrophy regression and arterial stiffness improvement in high-risk hypertensives. This view is enhanced by the new perspective of de Simone et al. 31 who recently proposed that PP is a sign of target organ damage rather than a traditional cardiovascular risk factor.
